Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis.
The pathogenesis of thrombocytopenia in patients with antiphospholipid syndrome (APS) is heterogeneous. Patients with antiphospholipid antibodies (aPL) and thrombocytopenia in the absence of clinical manifestations of APS will be diagnosed and treated as idiopathic thrombocytopenic purpura. However, the presence of aPL places those individuals at particular risk for developing both bleeding and thrombotic complications. Therefore, we propose the inclusion of such patients in the subgroup 'aPL-associated thrombocytopenia'. More attention should be devoted to this subgroup of patients to elucidate the role of aPL in the development of thrombocytopenia and to facilitate the adequate monitoring of its potential thrombotic risk.
Atsumi
T
T
Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan. at3tat@med.hokudai.ac.jp
Furukawa
S
S
Amengual
O
O
Koike
T
T
D017152:Antibodies, Antiphospholipid / Q000097:blood* / Q000502:physiology; D006801:Humans; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood* / Q000503:physiopathology / Q000517:prevention & control; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood* / Q000503:physiopathology / Q000517:prevention & control; D012307:Risk Factors
D017152:Antibodies, Antiphospholipid